Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
A Scientific Interpretation of Stock and Clinical Trial Data that's easy to understand
Check out Whatisthatdrug.com--new posts daily on drugs advertised in current media
Focal Adhesions: How cells crawl along
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
About Me
- Science Food Logic
- I have wet bench research experience in pharmacology, biochemistry and cell biology. Further, I have clinical research experience in ophthalmology, pathology and immunology. I am employed full time as a research scientist in the pharmaceutical industry. In my off time, I enjoy creating fine dining dishes as well as 20 minute meals that taste like fine dining. I like to teach both professionally and in the kitchen.
Blog Archive
-
▼
2006
(300)
-
▼
October
(114)
- Nasdaq update:
- Good Read about Stem Cells
- General Science News: Male contraceptive gets results
- Sirna soars after buyout deal afterhours!!!!
- Emisphere Technologies, Inc. Shares Fall On Mixed ...
- Update from post on 10-25-06! The vampire bats are...
- Point Therapeutics shares rise on osteosarcoma tri...
- Asian stocks were mixed to lower Monday
- Market outlook mixed for next week; Economy slows
- Man , another HCV polymerase inhibitor!
- Stocks seen higher but data may bring in cool front
- More bad news for Aspreva: MMF fails to meet Phase...
- Dow Ends Down 73 on Slow Economic Growth; BioTech ...
- Vertex Pharmaceuticals Incorporated (VRTX) Reports...
- Idenix Sees Positive HCV Study Results
- Nightly Asian Markey Update:
- Nasdaq joins the party while Biotech finishes up 1.3%
- Renovis stock collapses on NXY-059 Phase III effic...
- Market update 2:00PM
- EntreMed launches lung cancer trial for MKC-1
- Late night update: Nikkei advances; Honda shares r...
- Sanofi-Aventis cutting jobs in France:
- Forest Laboratories Release: Patient Recruitment F...
- Off topic: crude oil volitility
- Charges cost Elan
- Asian Markets follow U.S. ; Up early Wednesday; To...
- AstraZeneca wins approval from FDA for liquid Nexium
- ViroPharma and Wyeth Initiate Dosing in Phase 2 St...
- Replidyne stock crashes on FDA non approval letter
- Tapestry Pharma up 36% in morning trading:
- Wanted: Space for 'wet labs': Arizona's Biotech gr...
- STOCKS EXPECTED TO EXTEND RALLY THIS WEEK, BE READY
- U.S. stocks to take pause as focus turns to Fed
- Novartis stock up on FDA Gleevec approval
- The week's top news and analysis, Oct. 16-20
- Google extends rise after results; Lumera active
- MEMY Trial Halted...FDA wants more information
- Quick Market Update:
- Cytomedix Stock tumbles on FDA Ruling
- Another Hepatitis Protease Inhibitor: Vertex drug ...
- Expected Active Trading Tuesday
- Roche, InterMune Combine to develop hepatitis C ...
- Vical to Sell 2.5 Million Shares in Direct Offerin...
- DOW closing in on 12,000
- OMRIX Biopharmaceuticals Announces Positive Phase ...
- Pfizer Gets Into Vaccines
- Exelixis submits IND for XL281 RAF inhibitor
- Watch list for non Biotech stocks for Monday
- New River Pharmaceuticals Inc. Conducts End-Of-Pha...
- Saturday's Method : Flow Cytometry. Cell Sorting....
- I have to remember that .......
- BioTech down a bit: Nasdaq Composite Index gains 2...
- FDA Approves AstraZeneca's NEXIUM For The Treatme...
- Advancis Cuts Year Forecast on Keflex
- Volume Spikes CYTR AGAIN! Watching this one....
- Aspreva Sees 3Q Revenue Missing Street
- Discovery Laboratories Shares Up After Drug's Posi...
- Asia Follows the Bull...Right to the MONEY! Asian ...
- Lung cancer treatment gets FDA approval
- Genentech Recruiting for Eale's Disease Clinical T...
- Records Set yet Again! : Earnings help push Dow to...
- Wyeth initiates phase I trial of Rifampin on multi...
- Markets Higher in Asia up early Thursday
- Immucor tops analyst forcast: with blood machine:
- Immucor tops analyst forcast: with blood machine:
- XTL Biopharmaceuticals finishes up 16% today:
- Earnings Reports
- Genentech's 3Q Profit Surges 58 Percent!!
- Avanir Pharmaceuticals up 16% today
- Theravance, Inc. Announces Additional Results From...
- Asian Markets Rebound;
- New River Pharmaceuticals Gets Downgrade As Stock ...
- Stocks Expected to move on Tuesday:
- Monday: HDAC Inhibition and effect on DNA Replicat...
- FDA Approves Merck & Co., Inc. (MRK)'s ZOLINZA(TM)...
- Biotech Looks Set to Boil: Interesting article FYI
- FDA Approves Sepracor, Inc. BROVANA Inhalation So...
- I decided NOT to pull the trigger on Acordia:
- Keeping an eye on this one:
- Getting ready for a Bull week--
- Apoptosis
- Eli Lilly initiates Phase I trials, Stock price cl...
- Acordia volume, Price spike big moves
- Market Closed for the weekend:
- Decode shares plummet due to Phase III study stoppage
- It couldn't last forever... Wallstreet down
- Elan Extends Tysabri's Reach
- Friday's Methodology: PBMC
- Dynavax Technologies Positive Ragweed Data: Stock ...
- Dynavax Stock Soars: Shares up 55% on Ragweed Tria...
- Another Day, Another Record! Bulls win again.
- Today's Definition: Loss of Heterozygosity
- Big Action in Asia follows Dow Record Wednesday
- The top 5 BioTech Top Performers for Wednesday: FYI
- Drug stocks mixed, Vertex slides on widened loss
- ImClone climbs on renewed takeover speculation
- More Info on Human Genome Science's HGS004
- Human Genome Sciences Shares Jump
- Dow climbs new highs
- SkyePharma: Lodotra Phase III trial showed positiv...
-
▼
October
(114)
No comments:
Post a Comment